1. Scrip

Lots To Celebrate Among 2021 Drug Launches, But Underlying Trends Underwhelm

 
• By Jessica Merrill

The number of new drugs that launched in 2021 was on par with recent high trends, but launch trajectories generally underwhelmed commercially – except for COVID-19 vaccines.

hot air balloon with Scrip Perspectives badge
Some new launches struggled to get off the ground • Source: Alamy

It was a one-of-a-kind year for new drug launches in 2021. There was the unprecedented launch and commercial success of mRNA-based vaccines for COVID-19 on one end of the spectrum and the exceedingly disappointing launch of Biogen, Inc.'s much-hyped Aduhelm (aducanumab) for Alzheimer's disease on the other. In between there were a lot of launches, but also significant commercial headwinds that remained hard for the industry to overcome.

Overall, there were more than 50 new drugs and vaccines launched in the US in 2021 – a number that...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

Actuate Is Looking For A Buyer To Advance Pancreatic Cancer Candidate

 
• By Jessica Merrill

After presenting encouraging Phase II data on the GSK-3 inhibitor elraglusib at ASCO, Actuate Therapeutics is hoping to hold a pre-NDA meeting with the US FDA.

Novartis Upbeat Even With Entresto Expiry Looming

 
• By Kevin Grogan

Swiss major confident that new oncology drugs will fill revenue gap.

In Brief: Kezar Plots Lupus Revival For Zetomipzomib As FDA Lifts Hold On Hepatitis Trial

 
• By Manas Mishra

The go-ahead to resume a trial for its only drug candidate, zetomipzomib, in hepatitis could give Kezar a glimmer of hope of reviving another halted study in lupus nephritis.